Page 68 - MEMORIA ANUAL 2019 SEHH-FEHH

Programa EsPañol dE TraTamiEnTos En HEmaTología (PETHEma)
MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Ribera J, Granada I, Morgades M, Vives S, Genescà E, González C, Nomdedeu J, Escoda L, Montesinos P, Mercadal S, Coll R, González-Campos J, Abella E, Barba P, Bermúdez A, Gil C, Tormo M, Pedreño M, Martínez-Carballeira D, Hernández-Rivas JM, Orfao A, Martínez-López J, Esteve J, Bravo P, García-Guiñón A, Debén G, Morale- da JM, Queizán JA, Ortín X, Moreno MJ, Feliu E, Solé F, Ribera JM; PETHEMA Group, Spanish Society of Haematology. The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. Br J Haematol. 2019 Jul;186(2):263-8. doi: 10.1111/bjh.15887.
• Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, Topp MS. Blinatumomab for Acute Lym- phoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Trans- plantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1498-504. doi: 10.1016/j. bbmt.2019.04.010.
• Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol. 2019 Aug;94(8):853-61. doi: 10.1002/ajh.25507.
• Ribera J, Zamora L, Morgades M, Vives S, Granada I, Montesinos P, Gómez-Seguí I, Mercadal S, Guàrdia R, Nomdedeu J, Pratcorona M, Tormo M, Martínez-López J, Hernández-Rivas JM, Ciudad J, Orfao A, González-Campos J, Barba P, Escoda L, Esteve J, Genescà E, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B- cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2019 Nov;58(11):815-9. doi: 10.1002/gcc.22788.
• Jabbour E, Martinelli G, Vignetti M, Ribera JM, Gómez-Almaguer D, Minami Y, Xu J, Srivastava S, Neumann F, Kantarjian H. Ponatinib vs Imatinib with Reduced- Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chro- mosome-Positive (Ph plus ) ALL: Ph ALL CON Study. Clin Lymphoma Myeloma. 2019;19(Suppl. 1): S194-S194. Abstract: ALL-288.
• López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicen- te S, Fernández-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sam- pol A, Iniesta F, Ocio EM, Martín J, Rovira M, Cabero M, Castilla-Llorente C, Ribera
68